newsfilter
← Earnings
Earnings Releases·

Filana Therapeutics — Q3 2026 Earnings Summary

  • Net loss narrowed to $10.7 million ($0.22/share) in Q3 2026 from $10.8 million ($0.22/share) in Q3 2025, with total operating expenses for the first nine months falling to $31.8 million from $81.8 million the prior year.
  • The FDA lifted the clinical hold on simufilam for TSC-related epilepsy in September 2026, enabling a Phase 2a study of approximately 40 patients to begin screening by Q1 2027.
  • Cash and cash equivalents stood at $47.0 million as of September 30, 2026, with no debt; the company expects year-end cash between $38 million and $42 million after accounting for $31.25 million in restricted escrow funds for potential securities litigation.
  • Management initiated activation of clinical study sites immediately following the FDA decision, while R&D and G&A expenses decreased 2% and 6% respectively in Q3 2026 compared to the prior year period.
Company
FILANA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology